Canada Markets closed

FSD Pharma Inc. (HUGE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5400-0.0200 (-1.28%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Business Wire

    FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker

    TORONTO, September 22, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has retained the services of Hybrid Financial Ltd. ("Hybrid"), North Equities Corp. (the "North Equities"), Looking Glass Capital Consultants ("Looking Glass"), Worldwide Media Solutions, LLC ("BGTV Direct"), KCSA Strategic Communications ("KCSA"), and Digi Messagin

  • Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's Closing of its acquisition of Canadian Specialty Psychedelic Pharmaceutical Company Lucid Psycheceuticals - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - September 22, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, has closed its acquisition of Lucid Psycheceuticals. Founded in 2020, Lucid Psycheceuticals (www.LucidPsycheceuticals.com), a Canadian-based specialty psychedelic pharmaceutical company, is developing novel molecules and combinations

  • Business Wire

    FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

    TORONTO, September 21, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. ("Lucid"), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical n